Dr. Tahir Latif, MD
Claim this profileUniversity of Cincinnati Cancer Center-UC Medical Center
Studies Lymphoma
Studies B-Cell Lymphoma
10 reported clinical trials
31 drugs studied
Area of expertise
1Lymphoma
CCND1 positive
t(11;14) positive
Stage IV
2B-Cell Lymphoma
CCND1 positive
t(11;14) positive
Affiliated Hospitals
Clinical Trials Tahir Latif, MD is currently running
Duvelisib/CC-486 + Chemotherapy
for Lymphoma
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
Recruiting1 award Phase 227 criteria
IMPT-314
for Non-Hodgkin's Lymphoma
This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive B-cell NHL. Three cohorts of participants will be enrolled: 1) CAR T naïve after at least two or more prior lines of treatment, 2) CAR T experienced and 3) refractory disease or relapse within one year of first line therapy. Up to approximately 90 patients (30 per cohort) will be enrolled in dose finding Phase 1 part of the study, which will determine the recommended phase 2 dose. Phase 2 will enroll up to approximately 60 additional participants (20 per cohort) to evaluate further the safety and efficacy of IMPT-314. IMPT-314 treatment consists of a single infusion of CAR-transduced autologous T cells administered intravenously after a conditioning chemotherapy regimen consisting of fludarabine and cyclophosphamide, administered over 3 days. Individual participants will remain in the active post-treatment period for approximately 2 years. Participants will continue in long-term follow-up for 15 years from treatment.
Recruiting1 award Phase 1 & 2
More about Tahir Latif, MD
Clinical Trial Related1 year of experience running clinical trials · Led 10 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Tahir Latif, MD has experience with
- Rituximab
- Autologous Hematopoietic Stem Cell Transplantation
- Brentuximab Vedotin
- ALLO-647
- ALLO-501A
- Leucovorin Calcium
Breakdown of trials Tahir Latif, MD has run
Lymphoma
B-Cell Lymphoma
Mantle Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tahir Latif, MD specialize in?
Tahir Latif, MD focuses on Lymphoma and B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved CCND1 positive patients, or patients who are t(11;14) positive.
Is Tahir Latif, MD currently recruiting for clinical trials?
Yes, Tahir Latif, MD is currently recruiting for 3 clinical trials in Cincinnati Ohio. If you're interested in participating, you should apply.
Are there any treatments that Tahir Latif, MD has studied deeply?
Yes, Tahir Latif, MD has studied treatments such as Rituximab, Autologous Hematopoietic Stem Cell Transplantation, Brentuximab Vedotin.
What is the best way to schedule an appointment with Tahir Latif, MD?
Apply for one of the trials that Tahir Latif, MD is conducting.
What is the office address of Tahir Latif, MD?
The office of Tahir Latif, MD is located at: University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio 45219 United States. This is the address for their practice at the University of Cincinnati Cancer Center-UC Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.